CTP inhibitors are primarily used in the field of medical research and therapeutics, particularly in the treatment of cancer and viral infections. These inhibitors work by targeting cytidine triphosphate (CTP) synthesis, which is crucial for DNA and RNA production in rapidly dividing cells, such as cancer cells or virus-infected cells. By disrupting CTP synthesis, they effectively slow down or halt the proliferation of these cells.

In oncology, CTP inhibitors are explored as potential chemotherapeutic agents. They are designed to selectively target cancer cells, which rely heavily on nucleotide synthesis for their uncontrolled growth. This approach aims to minimize damage to healthy cells, reducing the side effects commonly associated with traditional chemotherapy.

Additionally, CTP inhibitors are being studied for their antiviral properties. Viruses depend on the host cell's nucleotide pool for replication, and inhibiting CTP synthesis can impair viral replication. This makes them a promising candidate for treating viral infections, including those caused by RNA viruses.

Research is ongoing to optimize the efficacy and specificity of CTP inhibitors, with the goal of developing safer and more effective treatments for cancer and viral diseases.